B+
Bull case
22%
Probability
Target price
$12.00
+149.0% vs current
XGN
ExagenANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$8.00
+66.0% vs current
B-
Bear case
28%
Probability
Target price
$4.00
-17.0% vs current
AI sentiment snapshot
Latest data as of 2026-06-03
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
-
Unavailable
AI commentary
Primary-source evidence supports a cautiously constructive monitoring view: Exagen delivered record Q1 2026 revenue, improved AVISE CTD volume and ASP, and reaffirmed FY2026 revenue guidance. The quality gate should remain tentative because no high-confidence forward company-specific catalyst is visible beyond continued commercial execution and financing/runway monitoring, direct operating peers are not well established in the packet, and analyst revision evidence is limited.
RankAlpha Sentiment Codex - 2026-06-03
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-11eventQ1 2026 execution update and guidance reaffirmationMedium impact
Exagen reported record Q1 2026 revenue of $17.3m (+12% y/y), AVISE CTD volume growth of 10%, trailing-twelve-month ASP of $444 (+6%), gross margin of 59.0%, and reaffirmed full-year 2026 revenue guidance of $70m-$73m. The same release showed cash and equivalents of about $21.5m and an adjusted EBITDA loss of $2.2m, so the evidence supports improved execution but not yet a proven profitability inflection. [#SEC-8K-2026-05-11]
2026-05-14catalystPost-print estimate digestion remains modest and thinly coveredMedium impact
Secondary post-print commentary said Q1 revenue was 5.5% above analyst forecasts and statutory losses were smaller than expected, with 2026 consensus revenue and loss-per-share forecasts nudged only modestly. That is mildly supportive, but the same commentary said the average target was unchanged at $8.67, so this is not enough to turn the memo into a catalyst-driven call. [#PR-EARNINGS-2026-05-14]
2026-12-31catalystFinancing and runway monitoring tied to path toward cash-flow positivityHigh impact
The FY2025 release said Exagen positioned its balance sheet to support its path to cash-flow positivity through a $20m public equity offering and a $25m credit facility, ending 2025 with $32.4m in cash, cash equivalents and restricted cash. Q1 2026 cash declined to about $21.5m while losses continued, so this is best treated as a long-horizon financing/runway monitoring catalyst rather than a high-conviction operating breakout. [#SEC-8K-2026-03-10] [#SEC-8K-2026-05-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology